IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Hematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 89/ 100
Competitive context
117 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 2 | BB |
Pegloticase M.D. Anderson Cancer Center | Phase 4 | BB |
Rasburicase M.D. Anderson Cancer Center | Phase 4 | BB |
METHOTREXATE Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | BB |
View all 50 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →